These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15742394)

  • 1. Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma.
    Jiang SY; Chou JM; Leu FJ; Hsu YY; Shih YL; Yu JC; Lee MS; Shyu RY
    World J Gastroenterol; 2005 Feb; 11(7):948-53. PubMed ID: 15742394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.
    Cirqueira CS; Felipe-Silva AS; Wakamatsu A; Marins LV; Rocha EC; de Mello ES; Alves VAF
    Pathol Oncol Res; 2019 Oct; 25(4):1363-1371. PubMed ID: 29464551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma.
    Shyu RY; Jiang SY; Chou JM; Shih YL; Lee MS; Yu JC; Chao PC; Hsu YJ; Jao SW
    Br J Cancer; 2003 Jul; 89(1):146-51. PubMed ID: 12838316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
    Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
    Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
    Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
    Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
    Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin.
    Asayama Y; Taguchi Ki K; Aishima Si S; Nishi H; Masuda K; Tsuneyoshi M
    Liver; 2002 Feb; 22(1):43-50. PubMed ID: 11906618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma.
    Batmunkh E; Tátrai P; Szabó E; Lódi C; Holczbauer A; Páska C; Kupcsulik P; Kiss A; Schaff Z; Kovalszky I
    Hum Pathol; 2007 Oct; 38(10):1508-15. PubMed ID: 17640714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Expression of Sonic Hedgehog Protein in Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Al-Bahrani R; Nagamori S; Leng R; Petryk A; Sergi C
    Pathol Oncol Res; 2015 Sep; 21(4):901-8. PubMed ID: 25740074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.
    Maeda T; Adachi E; Kajiyama K; Sugimachi K; Tsuneyoshi M
    Hum Pathol; 1995 Sep; 26(9):956-64. PubMed ID: 7545644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
    Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
    Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
    Zimmerman RL; Fogt F; Burke M; Murakata LA
    Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
    Radwan NA; Ahmed NS
    Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic features of combined hepatic carcinoma].
    He C; Yin HF; Liu P; Zhang Y; Zhang JB
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):824-8. PubMed ID: 24507101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
    Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.
    Ono Y; Hiratsuka Y; Murata M; Takasawa A; Fukuda R; Nojima M; Tanaka S; Osanai M; Hirata K; Sawada N
    Virchows Arch; 2016 Oct; 469(4):417-26. PubMed ID: 27444172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
    Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
    Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Yoon YI; Hwang S; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Lee JW; Hong SM; Yu ES; Lee SG
    J Gastrointest Surg; 2016 Feb; 20(2):411-20. PubMed ID: 26628072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.